Table 1.
PacELF leadership at WHO Division of Pacific Technical Support, Suva, Fiji, showing major strategies and achievements, 1999 to 2017
| 1999 to 2005: Dr. Kazuyo Ichimori | |
| • Baseline surveys conducted using ICT | |
| • Established a coordinating body and PacELF office and warehouse | |
| • Established logistics systems for drugs, diagnostics and data reporting | |
| • Regular program managers’ meetings | |
| • Development of M&E plan using A (baseline), B (sentinel), C (stop MDA), and D (transmission) surveys; C survey was in all ages and D survey in children | |
| • First countries stopped MDA in 2004 | |
| • Initiated morbidity surveys | |
| • Published PacELF book | |
| 2006 to 2008: Dr. Corinne Capuano | |
| • M&E guideline revision—maintained stop MDA (C) surveys in all ages and transmission surveys in children, with mop up around positive cases | |
| • Introduced test and treat strategies in three countries | |
| • Improvements to behavior change communication | |
| • Morbidity surveys and hydrocoele surgery programs in Fiji | |
| • Maintained MDA and post-MDA surveillance | |
| 2009 to 2011: Dr. Sunghye Kim | |
| • Preparation of elimination dossiers | |
| • Maintained MDA and post-MDA surveillance | |
| 2012 to 2017: Dr. Padmasiri Aratchige | |
| • Maintained MDA as needed and oversaw transmission assessment surveys | |
| • Validation of elimination dossiers approved for Vanuatu, Republic of Marshall Islands, Niue, Cook Is, and Tonga |